Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial

Annals of Oncology

Volumn 11, Issue 7, 2000, Pages 799-805

  Kosmidis, P ^a   Mylonakis, N ^b   Skarlos, D ^c   Samantas, E ^d   Dimopoulos, M ^e   Papadimitriou, C ^e   Kalophonos, C ^f   Pavlidis, N ^g   Nikolaidis, C ^g   Papaconstantinou, C ^h   Fountzilas, G ^h  

^a HYGEIA HOSPITAL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c Medical Center   (Greece)

^d Agii Anargyri Hospital   (Greece)

^e Alexandra's Hospital   (Greece)

^f UNIVERSITY OF PATRAS   (Greece)

^g UNIVERSITY OF IOANNINA   (Greece)

^h ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Dose response; NSCLC; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW DEPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG RESPONSE; FEMALE; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PACLITAXEL; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033811566     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008389402580     Document Type: Article

References (31)

1. Non-small-cell lung cancer
2. Cancer statistics 1998
3. Lung and larynx
4. Revisions in the international system for staging lung cancer
5. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
6. Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life
7. Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer
8. Taxol: Twenty years later the story unfolds
9. A phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer
10. Phase II study of Taxol, merbarone and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results
11. Chemotherapy in advanced inoperable non-small-cell lung cancer with paclitaxel: A phase II trial
12. Paclitaxel by one-hour infusion: An active drug in metastatic non-small-cell lung cancer
13. Sequences of Taxol and cisplatin: A phase I and pharmacologic study
14. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulation factor: Neuromuscular toxicity is dose-limiting
15. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group
16. Paclitaxel and Carboplatin in inoperable non-small-cell lung cancer: A phase II study
17. Paclitaxel and Carboplatin in combination in the treatment of advanced non-small-cell lung cancer. A phase II toxicity, response and survival analysis
18. Paclitaxel plus Carboplatin in advanced non-small-cell lung cancer: A phase II trial
19. A phase I trial of paclitaxel plus Carboplatin in untreated patients with advanced non-small-cell lung cancer
20. Phase I-II trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced non-small-cell lung cancer (NSCLC)
21. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer
22. Preliminary results of a dose-finding study of paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer
23. Toxicity and response criteria of the Eastern Cooperative Oncology Group
24. Exact inference for contingency tables with ordered categories
25. Asymptomatically efficient rank invariant test procedures
26. Non-parametric estimation from incomplete observations
27. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
28. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small-cell lung cancer
29. Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada clinical trials group